Improving Outcomes for Patients With CML: The Latest on TKIs and Combination Treatment Approaches

Thank you for your interest in attending the Clinical Care Options’ (CCO) symposium, Improving Outcomes for Patients With CML: The Latest on TKIs and Combination Treatment Approaches, originally scheduled for June 13, 2020, in Frankfurt, Germany. Due to the global impact of COVID-19, EHA organizers have decided to host the 25th EHA Congress in a virtual format.

As such, this live symposium will now be held as virtual live Webinar. The Webinar will still feature the original expert faculty, interactivity, evidence-based content, and panel discussions. When participating in the live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

If you’ve previously registered for the live symposium, your registration will be automatically converted to the live Webinar. No further action is needed; you will receive an email with a link to join in advance of the webinar.  

We look forward to having you join us for this interactive, live Webinar. In addition, we invite to you visit our Web site to access the many available online hematology and oncology programs and clinical resources.

Thank you,
CCO Member Service

Attend this live Webinar to hear CML experts from the United States and Europe discuss the latest treatment advances with the use of tyrosine kinase inhibitors in patients with chronic myeloid leukemia. 

Agenda

  • Program Overview
  • Primary Management of Chronic-Phase CML
  • Changing TKIs due to Intolerance: Second-line Therapy and Toxicity Management
  • Changing TKIs due to CML Progression: Second-line Therapy and Future Options
  • Closing Remarks and Question and Answer Session

Faculty

Goal Statement
The goal of this activity is to improve the competence of learners to apply the latest guidance and clinical data in the management of individuals with chronic myeloid leukemia.

Target Audience 
This program is intended for global hematologists, medical oncologists, and other clinicians who care for patients with CML.

Learning Objectives 

  • Manage treatment-related toxicities, such as GI toxicities, associated with use of TKIs in patients with CML
  • Increase patient involvement in the initiation of treatment, monitoring of response, managing toxicity, and adherence
  • Select individualized frontline therapy for patients with chronic-phase CML, taking into consideration patient age, medical history and comorbidities, and risk score (Sokal or Euro score)
  • Monitor first-line treatment responses and determine optimal timing of therapy changes
  • Evaluate the available evidence, potential predictive factors, patient preferences, and expert recommendations guiding potential therapy discontinuation and treatment-free remissions
  • Plan second-line, third-line, and later therapeutic strategies to manage resistance after previous TKI failure
  • Describe research to increase the number of patients able to discontinue treatment through combination of TKIs with novel agents

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.